Navigation Links
BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET
Date:3/28/2011

NOVATO, Calif., March 28, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 28, at 5:00 p.m. ET to discuss first quarter 2011 financial results.U.S. / Canada Dial-in Number:  888.396.2386International Dial-in Number:  617.847.8712Participant Code: 42725170Replay Dial-in Number: 888.286.8010Replay International Dial-in Number: 617.801.6888Replay Code: 56138656Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET
2. BioMarin to Present at the Barclays Capital Global Healthcare Conference
3. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
4. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
5. BioMarin to Present at the Morgan Stanley Healthcare Conference
6. BioMarin to Present at the Baird Healthcare Conference
7. BioMarin to Present at the Jefferies Healthcare Conference
8. BioMarin to Present at the Goldman Sachs Healthcare Conference
9. BioMarin to Present at the Deutsche Bank Health Care Conference
10. BioMarin to Present at the Baird Growth Stock Conference
11. BioMarin Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Vital Imaging ™ has ... California, San Diego for a joint study which aims ... (Magnetic Resonance Imaging) with that of a supine Dynawell ... pursuit of improved healthcare by combining cutting edge technology ... extremely valuable tool for evaluating pathological changes in the ...
(Date:5/21/2013)... SoundConnect is pleased to announce the release ... in Canada. Lync is the next generation of ... and organizations to collaborate and communicate much more easily ... the United States. With the progressive rollout of Lync ... Canada, SoundConnect now offers a complete Microsoft Lync solution ...
(Date:5/21/2013)... May 21, 2013 The Formulate Fusion ... solution for sales and marketing teams looking for a fully-functional ... the kit as “everything you’ll need to put together a ... Kit comes with a number of displays and accessories that ... 20 feet by 20 feet in size. These components vary ...
(Date:5/20/2013)... May 20, 2013 , ... Research Service (ARS) in treatment of mastitis ... , Trials to begin in the second half ... technology company Phosphagenics Limited (ASX: POH, OTCQX: ... (USDA) Agricultural Research Service (ARS) to develop and trial ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Phosphagenics Signs Research Agreement with the Agricultural Research Service 2
... Elekta, a global leader in radiation,oncology and ... at the 49th Annual Meeting of The American ... reduce,treatment times and increase efficiency. The meeting will ... Los Angeles Convention Center (Los Angeles,California, USA). Elekta ...
... N.J., Oct. 18 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ... cash tender offer for any and all of its ... at midnight, New,York City time, on October 17, 2007. ... offer, $171.2 million principal,amount of the notes, representing approximately ...
... Glycominds Ltd., a,biodiagnostics company specializing in glycan biomarkers ... cancer, announced today the,appointment of Dr. Chen Even ... Chen, a board member since 2004, contributes more ... "We are very pleased to elevate Dr. Even ...
Cached Biology Technology:Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 2Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 3Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 4NPS Pharmaceuticals Announces Results of Tender Offer 2NPS Pharmaceuticals Announces Results of Tender Offer 3Glycominds Appoints Board of Directors Chairman 2Glycominds Appoints Board of Directors Chairman 3
(Date:5/21/2013)... Chicago College of Medicine will study gender differences in how ... source -- and how changes in fat metabolism play a ... grant from the National Heart, Lung and Blood Institute. , ... energy. These changes may play a major role in the ... women, says E. Douglas Lewandowski, director of the UIC Center ...
(Date:5/21/2013)... Where? Copenhagen, Denmark: Bella Center Congress Centre ... , Why? An annual meeting focusing ... manufacturing and installation, drawing on leading experiences from all ... from a record of more than 900 abstracts received ... and oral presentations, more than 460 visual presentation, 55 ...
(Date:5/20/2013)... the antibiotic colistin are also commonly resistant to ... to a study in mBio , the ... Microbiology. Cross-resistance to colistin and host antimicrobials LL-37 ... bacterial attack, could mean that patients with life-threatening ... crippled immune response. Colistin is a last-line drug ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... A new study from The Montreal Neurological Institute and Hospital ... to discover a molecular link between Parkinson,s disease and defects ... published in the prestigious journal Molecular Cell and ... , provides new insight into the mechanisms underlying Parkinson,s disease, ...
... the molecular process that can shut down a marauding, ... who suffer battlefield casualties, heart attacks, strokes, automobile accidents ... the January edition of Molecular Immunology. , The ... of a reaction first observed in the lab by ...
... Diseases (NIAID), part of the National Institutes of Health ... Tulane University for its ongoing efforts to treat and ... threatens hundreds of thousands of people annually in West ... The contract will include collaboration between Tulane; Scripps ...
Cached Biology News:Communication breakdown: what happens to nerve cells in Parkinson's disease 2Communication breakdown: what happens to nerve cells in Parkinson's disease 3Research could lead to way to halt deadly immune response 2Research could lead to way to halt deadly immune response 3Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2
Peptide-affinity Purified Polyclonal Antibody to MTR...
Purified anti-eIF-4E...
Purified anti-PXR...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Biology Products: